GO
Loading...

Achillion Pharmaceuticals Inc

More

  • US STOCKS-Wall St edges up, S&P rises back above 2,000 Tuesday, 26 Aug 2014 | 10:35 AM ET

    *Best Buy tumbles after results, DSW higher. *Digital Ally gains again, has tripled this month. "People aren't going to do anything too aggressive until there's some kind of catalyst, either positive or negative, and we may end up consolidating around 2,000 for a while," said Michael O'Rourke, chief market strategist at JonesTrading in Greenwich, Connecticut.

  • *Best Buy tumbles after results, DSW higher. *Digital Ally gains before bell, has tripled this month. Nonetheless, further gains may be a challenge without positive catalysts and amid potential headwinds such as a reduction in Federal Reserve stimulus and a simmering conflict between Ukraine and Russia.

  • *Digital Ally gains before bell, has tripled this month. NEW YORK, Aug 26- U.S. stock index futures were little changed on Tuesday, with investors finding few reasons to buy after a rally in the previous session that took the S&P 500 above 2,000 for the first time.

  • Aug 15- Achillion Pharmaceuticals Inc said all patients treated with its experimental hepatitis C drug showed no detectable levels of the virus four weeks after the therapy, sending its shares up 18 percent. Achievement of 100 percent cure rate confirms the competitive profile of NS5A, Wells Fargo Securities analyst Brian Abrahams wrote in a note.

  • Aug 15- Achillion Pharmaceuticals Inc said interim results from a mid-stage trial showed that all patients given its experimental hepatitis C drug showed no detectable levels of the virus four weeks after completing the therapy.

  • Midday Movers: Wal-Mart, Tekmira, Tesla & more Monday, 11 Aug 2014 | 12:32 PM ET
    NYSE exchange floor

    Take a look at some of Monday's midday movers:

  • Midday movers: Medtronic, Netflix, Tesla Motors & More Monday, 16 Jun 2014 | 12:12 PM ET
    NYSE EuroNext flag hangs outside the NYSE.

    Some of Monday's midday movers:

  • *S&P 500 breaks string of record high closes. *Achillion Pharmaceuticals soars in heavy volume. NEW YORK, June 10- U.S. stocks finished nearly flat on Tuesday, although the Dow eked out another record closing high as utilities' shares fell while 10- year bond yields hit their highest level in a month.

  • *Achillion Pharmaceuticals jumps in heavy volume. Facebook Inc rose 4.3 percent to $65.59. Netflix Inc gained 1.4 percent to $429.11.

  • Investors eye Achillion for next big pharma deal Tuesday, 10 Jun 2014 | 2:20 PM ET
    Achillion web page

    Achillion's been a takeover target for years. But Merck's acquisition of Idenix may mean Achillion's time has come.

  • Midday movers: Allergan, Five Below, Netflix & More Tuesday, 10 Jun 2014 | 1:11 PM ET

    Some of Tuesday's midday movers:

  • NEW YORK, June 10- U.S. stocks fell modestly on Tuesday as investors found few reasons to keep buying with the Dow and S&P 500 coming off a string of record highs. Facebook Inc rose 3.5 percent to $65.05 while Netflix Inc was up 2.7 percent to $434.51. Tuesday's decline comes after a string of gains for Wall Street.

  • US STOCKS-Wall St recedes modestly from record levels Tuesday, 10 Jun 2014 | 10:14 AM ET

    NEW YORK, June 10- U.S. stocks fell modestly on Tuesday as investors found few reasons to keep buying with the Dow and S&P 500 coming off a string of record highs. Facebook Inc rose 2.6 percent to $64.50 while Netflix Inc was up 2.3 percent to $432.94. Tuesday's decline comes after a string of gains for Wall Street.

  • June 10- Achillion Pharmaceuticals Inc said the U.S. Food and Drug Administration allowed it to resume the development of one of its hepatitis C drugs, lifting a clinical hold that was imposed nearly a year ago.

  • NEW YORK, June 10- U.S. stock index futures edged lower on Tuesday, as investors found few reasons to keep buying with the Dow and S&P 500 just below the latest in a string of records.

  • June 10- Achillion Pharmaceuticals Inc said the U.S. Food and Drug Administration allowed it to resume the development of one of its hepatitis C drugs, lifting a clinical hold that was imposed nearly a year ago. Achillion submitted additional data on the drug in September, but the FDA maintained the hold.

  • NEW YORK, June 10- U.S. stock index futures edged lower on Tuesday, as investors found few reasons to keep buying with the Dow and S&P 500 just off the latest in a string of records.

  • Midday movers: Apple, McDonald's, NeuStar & More Monday, 9 Jun 2014 | 12:01 PM ET
    NYSE EuroNext flag hangs outside the NYSE.

    Some of Monday's midday movers:

  • Merck to buy Idenix to boost hepatitis C pipeline Monday, 9 Jun 2014 | 9:42 AM ET
    Merck employees walk past a Merck sign in front of the company's building in Summit, New Jersey.

    Drug giant Merck said it would purchase Idenix Pharmaceuticals for $3.85 billion, a deal already approved by both companies' board of directors.

  • Pharma offering new hope for hepatitis C patients Wednesday, 26 Feb 2014 | 1:21 PM ET
    Hepatitis C virus

    New pill treatments show better cure rates and fewer side effects. Here are the companies behind those therapies.